This list contains information about the development status of unapproved drugs or unapproved indications. Nothing herein are intended to constitute promotion or advertisement of pharmaceutical products (including products currently in development).
IND Code |
Dosage Form | Features | Indications | Development Locations | Development Stage |
TAS-114 | Oral | dUTPase inhibitor | Non-small cell lung cancer (NSCLC) | Japan | Phase II |
US | Phase II | ||||
Europe | Phase II | ||||
TAS-115 | Oral | Multi-kinase inhibitor | Prostate cancer | Japan | Phase II |
Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype | Japan | Phase II | |||
Osteosarcoma | Japan | Phase III | |||
TAS-116 | Oral | HSP90 inhibitor | Gastrointestinal stromal tumor (GIST) | Japan | Filed |
Solid tumors | US | Phase I | |||
Europe | Phase I | ||||
TAS-117 | Oral | AKT inhibitor | Solid tumors with germline PTEN mutations | Japan | Phase II |
US | Phase II | ||||
Europe | Phase II | ||||
TAS-120 |
Oral | FGFR inhibitor | Cholangiocarcinoma | Japan | Phase III |
US | Filed | ||||
Europe | Phase III | ||||
Breast cancer | US | Phase II | |||
Europe | Phase II | ||||
FGFR aberrations cancer | Japan | Phase II | |||
US | Phase II | ||||
Europe | Phase II | ||||
Urothelial cancer | US | Phase II | |||
Europe | Phase II | ||||
TAS0313 | Injection | Peptide vaccine | Urothelial cancer | Japan | Phase II |
TAS3681 | Oral | Prostate cancer | US | Phase I | |
Europe | Phase I | ||||
TAS0728 | Oral | Solid tumors | US | Phase Ⅰ/II | |
Europe | Phase Ⅰ/II | ||||
TAS0612 | Oral | Solid tumors | US |
Phase Ⅰ |
|
Europe | Phase Ⅰ | ||||
TAS0953 | Oral | Solid tumors | Japan | Phase Ⅰ/II | |
TAS2940 | Oral | Solid tumors | US | Phase Ⅰ | |
Europe | Phase Ⅰ | ||||
ET-743 | Injection | Ovarian cancer | Japan | Phase Ⅰ | |
AB122 | Injection | Solid tumors | Japan | Phase Ⅰ | |
AB122+TAS116 | Injection + oral | Solid tumors | Japan | PhaseⅠ | |
TAS-205 | Oral | PGD synthase inhibitor | Duchenne muscular dystrophy(DMD) | Japan | Phase III |
TAS5315 | Oral | BTK inhibitor | Rheumatoid arthritis(RA) | Japan | Phase II |
TAC-302 | Oral | Detrusor underactivity with overactive bladder | Japan | Phase II | |
TAS-303 | Oral | Selective noradrenalin reuptake inhibitor | Stress urinary incontinence | Japan | Phase II |
As of Mar. 31, 2022